ClinicalTrials.gg
CompletedNCT03629509BEFOREUpdated Oct 26, 2026Results posted

Implementation of the Begin Exploring Fertility Options, Risks and Expectations (BEFORE) Decision Aid

An interventional study of Educational Webinar and Resources in Evaluation Studies, Implementation Research and Decision Aid, sponsored by Unity Health Toronto. Completed at 1 site in Canada. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Health services research

How we know

Updated Oct 26, 2026Now CompletedResults posted+12 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.

Enrollment
457th of 787
116 · median 155
Started
2018
with 40 others
No phase
204 of 907
37 open now
Registered
590th of 907
by date

Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 457th largest by enrollment of the 787 interventional ones that give a count, is one of 41 that started in 2018, is one of 204 with no phase, and was the 590th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Breast Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The Begin Exploring Fertility Options, Risks and Expectations (BEFORE) decision aid was created to support fertility discussions and decision-making for young breast cancer patients in Canada. While decision aids are valuable as an adjunct to consultations with health care providers, successful implementation in clinical settings following development remains low.

This goal of this study was to evaluate the effectiveness of an educational intervention (a one-hour webinar targeted to oncology nurses introducing the BEFORE decision aid, and posters and handouts in clinical settings) on health care provider recommendations of fertility tools to young breast cancer patients. The main question aims to answer:

- What is the proportion of patients who were planning or were unsure about having future children who reported their health care provider recommended fertility tools following the intervention?

Data from a fertility questionnaire that young breast cancer patients are completing as part of an ongoing prospective cohort study in Canada will be used to answer the main question.

Read the detailed description

A pragmatic stepped wedge cluster randomized trial was completed by sequentially administering an educational intervention and implementing the BEFORE decision aid in 19 centres across Canada that were recruiting young breast cancer patients for the Reducing the bUrden of Breast cancer in Young women (RUBY) Study (https://www.rubystudy.ca/Home).

There were 19 participating RUBY centres grouped into 12 clusters (1 to 3 centres per cluster). The intervention was sequentially rolled out to all centres between March 2019 and January 2020. Two clusters moved from the control period to the intervention period every 7 weeks (called a 'step'). There was 6 steps plus a baseline step during the study period. At the end of the study period all clusters (i.e., participating RUBY sites) received the intervention. The time-point of when the clusters were switched from control to intervention and the two clusters that received the intervention together was randomized.

Eligible participants included those who indicated they were planning or were unsure about having future children and were enrolled in the RUBY study during the study period. The data collection includes obtaining secondary data collected as part of the RUBY study. Specifically, demographic data and data from a fertility questionnaire completed at 3-months following enrollment in the RUBY study was used to determine the primary outcome.

The primary outcome was the number of patients reporting that their health care provider recommended fertility tools. We hypothesized that following the intervention a 20% difference would be observed, from 10% in the control period to 30% in the intervention period, in the number of patients who report that someone in their care team recommended a fertility tool.

03

Conditions studied

  • Evaluation Studies
  • Implementation Research
  • Decision Aid
  • Young Adult Cancer
  • Educational Intervention
  • Fertility Perservation
  • Breast Cancer

Browse trials for

Keywords

  • decision aid
  • breast cancer
  • young females
  • implementation
  • stepped wedge trial
  • education
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Eligible patients included those enrolled in the RUBY study during the study period who indicated on a 3-month fertility questionnaire that they were unsure or planning on having one of more (additional) children in the future.

The RUBY study eligibility criteria includes:

  • Canadian women between 18 and 40 years of age
  • Newly diagnosed with breast cancer (invasive, ductal carcinoma in situ or malignant phyllodes)
  • Able to provide and complete required questionnaires
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Educational Webinar and Resources (EWR)

    The educational intervention included two aspects: 1. A one hour webinar was conducted with health care providers. The target audience was oncology nurses but any health care provider that discussed fertility with breast cancer patients was able to participate. The webinar was interactive and included an overview of oncofertility, explained how treatment can cause infertility, and provided information on the fertility preservation options available before and after treatment, approximate cost of fertility preservation in Canada, fertility resources, and how to overcome barriers in oncofertility. The webinar also provided an overview on the BEFORE decision aid development and content, along with training on use of the tool in clinical settings. 2. We advertised the availability of the BEFORE decision aid through posters and handouts in clinic areas at each of the centres.

    Behavioral: Educational Webinar and Resources

  • No intervention
    No Educational Webinar and Resources (No EWR)

    Participants in this group did not receive the educational webinar or resources intervention.

Interventions

  • BehavioralEducational Webinar and Resources

    Educational webinar and resources on oncofertility and the BEFORE decision aid

06

What researchers measure

Primary outcomes

  1. Patient-reported Outcome Questionnaire - Fertility Preservation Questionnaire

    The number of patients reporting that their health care provider recommended fertility tools

    Time frame: 3 months from date of randomization

07

Results

Posted Oct 26, 2026
Limitations and caveats
The overall sample size was lower than estimated. A sample size of 168 patients was calculated to have sufficient power of 84% to detect the primary outcome, thus the study may have been underpowered. Data was only obtained from patients participating in the RUBY study. Privacy policies at centres restricted the ability to contact webinar attendees so no data was obtained to assess the feasibility, acceptability, suitability, usability, barriers and facilitators of the BEFORE decision aid.

Participant flow

All enrolled RUBY study participants at 19 centres across Canada who indicated they were planning or unsure about having future children. Overall study period was July 30, 2018 - November 11, 2018 (baseline step) and March 18, 2019 - March 2, 2020 (intervention period).

Step 1-Jul 30, 2018 - Nov 11, 2018
Participant flow — Step 1-Jul 30, 2018 - Nov 11, 2018
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started440
Completed440
Not completed00
Step 2 - March 18, 2019 -May 5, 2019
Participant flow — Step 2 - March 18, 2019 -May 5, 2019
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started9NA
Completed9NA
Not completed0NA
Step 3-May 6, 2019 - Jun 23, 2019
Participant flow — Step 3-May 6, 2019 - Jun 23, 2019
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started105
Completed105
Not completed00
Step 4 - Jun 24, 2019 - Aug 11, 2019
Participant flow — Step 4 - Jun 24, 2019 - Aug 11, 2019
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started23
Completed23
Not completed00
Step 5 - Aug 12, 2019 - Sept 29, 2019
Participant flow — Step 5 - Aug 12, 2019 - Sept 29, 2019
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started23
Completed23
Not completed00
Step 6 - Sept 30, 2019 - Nov 17, 2019
Participant flow — Step 6 - Sept 30, 2019 - Nov 17, 2019
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started110
Completed110
Not completed00
Step 7 - Nov 18, 2019 - Jan 19, 2020
Participant flow — Step 7 - Nov 18, 2019 - Jan 19, 2020
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started015
Completed015
Not completed00
Step 8 Jan 20, 2020 - Mar 2, 2020
Participant flow — Step 8 Jan 20, 2020 - Mar 2, 2020
MilestoneNo Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)
Started012
Completed012
Not completed00

Outcome measures

PrimaryPatient-reported Outcome Questionnaire - Fertility Preservation Questionnaire

The number of patients reporting that their health care provider recommended fertility tools

Time frame:
3 months from date of randomization
Reported as:
Count of participants · Participants
Patient-reported Outcome Questionnaire - Fertility Preservation Questionnaire
ParticipantsNo Educational Webinar and Resources (No EWR)Educational Webinar and Resources (EWR)
Patient-reported Outcome Questionnaire - Fertility Preservation Questionnaire1416
Statistical analysis
  • No Educational Webinar and Resources (No EWR) vs Educational Webinar and Resources (EWR) · Mixed-effect logistic regression · p = 0.125 · Odds ratio (or): 1.93 · 95% CI 0.83 to 4.47A mixed-effect logistic regression model with a random effect for centre was used to determine the primary outcome.

Adverse events

Collected over NA - AEs were not monitored/assessed. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
No Educational Webinar and Resources (No EWR)———
Educational Webinar and Resources (EWR)———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)No Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)Total
<=18 years000
Between 18 and 65 years6848116
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)No Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)Total
Female6848116
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)No Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)Total
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)No Educational Webinar and Resources (EWR)Educational Webinar and Resources (EWR)Total
Canada6848116
08

Study locations

1 site
  • Unity Health Toronto
    Toronto, Ontario M5B 1W8, Canada
09

References and documents

Publications

  • Speller B, Metcalfe K, Kennedy ED, Facey M, Greenblatt E, Scheer AS, Warner E, Joy AA, Wright FC, Baxter NN. The "Begin Exploring Fertility Options, Risks and Expectations" (BEFORE) decision aid: development and alpha testing of a fertility tool for premenopausal breast cancer patients. BMC Med Inform Decis Mak. 2019 Oct 28;19(1):203. doi: 10.1186/s12911-019-0912-y. PubMed 31660965 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Mar 2020, 19 months.

Results were first posted in Oct 2026, 6 years 7 months after primary completion.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 19 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Sep 2018 → Jul 2018, primary completion Oct 2019 → Mar 2020 and completion Dec 2019 → Mar 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 14, 2018
StartActual
Jul 30, 2018was Sep 2018
Primary completionActual
Mar 2, 2020was Oct 2019
CompletionActual
Mar 2, 2020was Dec 2019
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 26, 2026
Results
Results posted
posted Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • Unity Health Toronto · Toronto, Canada
Show 1 removed
  • St. Michael's Hospital · Toronto, Canada
Oct 26, 2026
Start date
Sep 1, 2018→Jul 30, 2018 (actual)
Oct 26, 2026
Primary completion
Oct 1, 2019→Mar 2, 2020 (actual)
Oct 26, 2026
Study completion
Dec 31, 2019→Mar 2, 2020 (actual)
Oct 26, 2026
Enrollment
224 (estimated)→116 (actual)
Oct 26, 2026
Eligibility
Criteria largely rewritten (9 changes)
What changed in the criteria
  • RemovedInclusion Criteria:
  • RemovedYoung females diagnosed with histologically-confirmed breast cancer will be eligible to participate if they:
  • Removedare age =18 years and prior to their 41st birthday;
  • AddedEligible patients included those enrolled in the RUBY study during the study period who indicated on a 3-month fertility questionnaire that they were unsure or planning on having one of more (additional) children in the future.
  • AddedThe RUBY study eligibility criteria includes:
  • AddedCanadian women between 18 and 40 years of age
  • AddedNewly diagnosed with breast cancer (invasive, ductal carcinoma in situ or malignant phyllodes)
  • Editedare ableAble to provide verbal informed consent and complete the interviews in English or French;required questionnaires
  • Removedcompleted the 3-month fertility questionnaire as part of the RUBY Study.
Oct 26, 2026
Interventions
Added Behavioral: Educational Webinar and Resources; removed Behavioral: BEFORE decision aid. Arms added: Educational Webinar and Resources (EWR)·No Educational Webinar and Resources (No EWR); arms removed: Pre-Intervention·BEFORE Decision Aid Intervention·Post-Intervention
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPatient-reported outcome questionnaireOutcome Questionnaire - Fertility Preservation QuestionnaireTime frame: 3 months from date of randomization
Oct 26, 2026
Documents
Secondary outcomes
9 removed
What changed in the outcomes
  • RemovedBEFORE decision aid online survey - Provider Recommendation of Decision AidTime frame: From date of randomization until the end of the study at 48 weeks
  • RemovedBEFORE decision aid online survey - Patient Learning About Decision AidTime frame: From date of randomization until the end of the study at 48 weeks
  • RemovedBEFORE decision aid online survey - Patient SatisfactionTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - Number of VisitsTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - Length of VisitsTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - Most Visited PageTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - Least Visited PageTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - Decision Aid DownloadTime frame: From date of randomization until the end of the study at 48 weeks
  • Removedother outcomeGoogle Analytics - User LocationTime frame: From date of randomization until the end of the study at 48 weeks
Oct 26, 2026
Title
BEFORE Decision Aid Implementation Study→Implementation of the Begin Exploring Fertility Options, Risks and Expectations (BEFORE) Decision Aid
Oct 26, 2026
Sponsor
Collaborators added: Canadian Cancer Society (CCS); collaborators removed: Canadian Breast Cancer Foundation
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Status unknown→Completed
    Results posted
    1 site added, 1 site removed
    Show site
    • Unity Health Toronto · Toronto, Canada
    Show 1 removed
    • St. Michael's Hospital · Toronto, Canada
    Start date Sep 1, 2018→Jul 30, 2018 (now actual)
    Primary completion Oct 1, 2019→Mar 2, 2020 (now actual)
    Study completion Dec 31, 2019→Mar 2, 2020 (now actual)
    Enrollment 224 (estimated)→116 (actual)
    Eligibility Criteria largely rewritten (9 changes)
    What changed in the criteria
    • RemovedInclusion Criteria:
    • RemovedYoung females diagnosed with histologically-confirmed breast cancer will be eligible to participate if they:
    • Removedare age =18 years and prior to their 41st birthday;
    • AddedEligible patients included those enrolled in the RUBY study during the study period who indicated on a 3-month fertility questionnaire that they were unsure or planning on having one of more (additional) children in the future.
    • AddedThe RUBY study eligibility criteria includes:
    • AddedCanadian women between 18 and 40 years of age
    • AddedNewly diagnosed with breast cancer (invasive, ductal carcinoma in situ or malignant phyllodes)
    • Editedare ableAble to provide verbal informed consent and complete the interviews in English or French;required questionnaires
    • Removedcompleted the 3-month fertility questionnaire as part of the RUBY Study.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPatient-reported outcome questionnaireOutcome Questionnaire - Fertility Preservation QuestionnaireTime frame: 3 months from date of randomization
    Secondary outcomes 9 removed
    What changed in the outcomes
    • RemovedBEFORE decision aid online survey - Provider Recommendation of Decision AidTime frame: From date of randomization until the end of the study at 48 weeks
    • RemovedBEFORE decision aid online survey - Patient Learning About Decision AidTime frame: From date of randomization until the end of the study at 48 weeks
    • RemovedBEFORE decision aid online survey - Patient SatisfactionTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - Number of VisitsTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - Length of VisitsTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - Most Visited PageTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - Least Visited PageTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - Decision Aid DownloadTime frame: From date of randomization until the end of the study at 48 weeks
    • Removedother outcomeGoogle Analytics - User LocationTime frame: From date of randomization until the end of the study at 48 weeks
    Interventions Added Behavioral: Educational Webinar and Resources; removed Behavioral: BEFORE decision aid. Arms added: Educational Webinar and Resources (EWR)·No Educational Webinar and Resources (No EWR); arms removed: Pre-Intervention·BEFORE Decision Aid Intervention·Post-Intervention
    Sponsor Collaborators added: Canadian Cancer Society (CCS); collaborators removed: Canadian Breast Cancer Foundation
    Title BEFORE Decision Aid Implementation Study→Implementation of the Begin Exploring Fertility Options, Risks and Expectations (BEFORE) Decision Aid
    + 9 other changes: registry notes, index terms, verification date, description, conditions, design details, contact details, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03629509
Collaborators
Applied Health Research Centre, Canadian Institutes of Health Research (CIHR), Canadian Cancer Society (CCS)
Responsible party
Nancy Baxter (Chief of General Surgery, Scientist, Unity Health Toronto) — Principal investigator
First posted
Aug 14, 2018
Start date
Jul 30, 2018
Primary completion
Mar 2, 2020
Completion
Mar 2, 2020
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Study contacts

Nancy N Baxter, MD, FRCSC, FACS, PhD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion